Department of Chemistry, University of Zurich, CH-8057 Zurich, Switzerland.
Department of Chemistry, University of Zurich, CH-8057 Zurich, Switzerland
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1366-E1373. doi: 10.1073/pnas.1714790115. Epub 2018 Jan 29.
Many drugs require extensive metabolism en route to their targets. High-resolution visualization of prodrug metabolism should therefore utilize analogs containing a small modification that does not interfere with its metabolism or mode of action. In addition to serving as mechanistic probes, such analogs provide candidates for theranostics when applied in both therapeutic and diagnostic modalities. Here a traceable mimic of the widely used anticancer prodrug cytarabine (ara-C) was generated by converting a single hydroxyl group to azide, giving "AzC." This compound exhibited the same biological profile as ara-C in cell cultures and zebrafish larvae. Using azide-alkyne "click" reactions, we uncovered an apparent contradiction: drug-resistant cells incorporated relatively large quantities of AzC into their genomes and entered S-phase arrest, whereas drug-sensitive cells incorporated only small quantities of AzC. Fluorescence microscopy was used to elucidate structural features associated with drug resistance by characterizing the architectures of stalled DNA replication foci containing AzC, EdU, γH2AX, and proliferating cell nuclear antigen (PCNA). Three-color superresolution imaging revealed replication foci containing one, two, or three partially resolved replication forks. Upon removing AzC from the media, resumption of DNA synthesis and completion of the cell cycle occurred before complete removal of AzC from genomes in vitro and in vivo. These results revealed an important mechanism for the low toxicity of ara-C toward normal tissues and drug-resistant cancer cells, where its efficient incorporation into DNA gives rise to highly stable, stalled replication forks that limit further incorporation of the drug, yet allow for the resumption of DNA synthesis and cellular division following treatment.
许多药物在到达靶点之前需要广泛的代谢。因此,前药代谢的高分辨率可视化应该利用含有小修饰的类似物,这些修饰物不会干扰其代谢或作用模式。除了作为机制探针外,此类类似物在治疗和诊断模式中应用时,也可作为治疗和诊断候选物。在这里,通过将单个羟基转化为叠氮化物,生成了广泛使用的抗癌前药阿糖胞苷(ara-C)的可追踪模拟物“AzC”。该化合物在细胞培养物和斑马鱼幼虫中表现出与 ara-C 相同的生物学特征。使用叠氮化物-炔烃“点击”反应,我们发现了一个明显的矛盾:耐药细胞将相对大量的 AzC 掺入其基因组并进入 S 期停滞,而敏感细胞仅掺入少量的 AzC。荧光显微镜用于阐明与耐药性相关的结构特征,方法是对含有 AzC、EdU、γH2AX 和增殖细胞核抗原(PCNA)的停滞 DNA 复制焦点的结构进行特征描述。三色超分辨率成像揭示了含有一个、两个或三个部分解析复制叉的复制焦点。当从培养基中去除 AzC 时,在体外和体内从基因组中完全去除 AzC 之前,DNA 合成的恢复和细胞周期的完成发生。这些结果揭示了 ara-C 对正常组织和耐药癌细胞的低毒性的一个重要机制,其中其有效地掺入 DNA 会产生高度稳定的停滞复制叉,从而限制了药物的进一步掺入,但允许在治疗后恢复 DNA 合成和细胞分裂。